{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T02:32:37Z","timestamp":1781577157904,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Teva Branded Pharmaceutical Products R&D LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s12325-025-03329-x","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T14:14:13Z","timestamp":1757340853000},"page":"5564-5577","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Switching Patients with Schizophrenia from Intramuscular Paliperidone Palmitate Once Monthly to TV-46000, a Long-Acting Subcutaneous Antipsychotic: Population Pharmacokinetic\u2013Based Strategies"],"prefix":"10.1007","volume":"42","author":[{"given":"Itay","family":"Perlstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqi","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Ivaturi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelli R.","family":"Franzenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Suett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avia","family":"Merenlender Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arti","family":"Phatak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2719-4573","authenticated-orcid":false,"given":"Rajendra","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"3329_CR1","doi-asserted-by":"publisher","first-page":"15067","DOI":"10.1038\/nrdp.2015.67","volume":"1","author":"RS Kahn","year":"2015","unstructured":"Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1:15067.","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"3329_CR2","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","volume":"177","author":"GA Keepers","year":"2020","unstructured":"Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868\u201372.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"3329_CR3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S2215-0366(21)00039-0","volume":"8","author":"T Kishimoto","year":"2021","unstructured":"Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry. 2021;8(5):387\u2013404.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"3329_CR4","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s12325-022-02354-4","volume":"40","author":"MC Dickson","year":"2023","unstructured":"Dickson MC, Nguyen MM, Patel C, et al. Adherence, persistence, readmissions, and costs in Medicaid members with schizophrenia or schizoaffective disorder initiating paliperidone palmitate versus switching oral antipsychotics: a real-world retrospective investigation. Adv Ther. 2023;40(1):349\u201366.","journal-title":"Adv Ther"},{"issue":"5","key":"3329_CR5","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/YIC.0b013e328354b534","volume":"27","author":"EJ Duncan","year":"2012","unstructured":"Duncan EJ, Woolson SL, Hamer RM. Treatment compliance in veterans administration schizophrenia spectrum patients treated with risperidone long-acting injectable. Int Clin Psychopharmacol. 2012;27(5):283\u201390.","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"3329_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40261-020-00990-8","volume":"41","author":"J Mahlich","year":"2021","unstructured":"Mahlich J, Olbrich K, Wilk A, Wimmer A, Wolff-Menzler C. Time to treatment discontinuation in German patients with schizophrenia: long-acting injectables versus oral antipsychotics. Clin Drug Investig. 2021;41(1):99\u2013113.","journal-title":"Clin Drug Investig"},{"issue":"9","key":"3329_CR7","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/eip.13384","volume":"17","author":"S Schwartz","year":"2023","unstructured":"Schwartz S, Lee S, Coble EB, Troxler C, Toscano S, Kumar A. Time-to-therapy discontinuation in patients newly diagnosed with schizophrenia initiated on long-acting injectable versus oral dopamine receptor blocking agents. Early Interv Psychiatry. 2023;17(9):921\u20138.","journal-title":"Early Interv Psychiatry"},{"issue":"4","key":"3329_CR8","doi-asserted-by":"publisher","first-page":"21r14153","DOI":"10.4088\/JCP.21r14153","volume":"83","author":"SC Fang","year":"2022","unstructured":"Fang SC, Huang CY, Shao YJ. Long-term outcomes of early use of long-acting injectable antipsychotics in schizophrenia. J Clin Psychiatry. 2022;83(4):21r14153.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"3329_CR9","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1093\/schbul\/sbac046","volume":"48","author":"YH Lin","year":"2022","unstructured":"Lin YH, Wu CS, Liu CC, Kuo PH, Chan HY, Chen WJ. Comparative effectiveness of antipsychotics in preventing readmission for first-admission schizophrenia patients in national cohorts from 2001 to 2017 in Taiwan. Schizophr Bull. 2022;48(4):785\u201394.","journal-title":"Schizophr Bull"},{"issue":"9","key":"3329_CR10","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1080\/03007995.2022.2101819","volume":"38","author":"LM Tidmore","year":"2022","unstructured":"Tidmore LM, Keast SL, Waters HC, Pareja KL, Cothran T, Skrepnek GH. Readmissions, costs, and duration to subsequent outpatient visit after hospital discharge among Medicaid beneficiaries utilizing oral versus long-acting injectable antipsychotics in bipolar disorder or schizophrenia. Curr Med Res Opin. 2022;38(9):1621\u201330.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"3329_CR11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/YIC.0000000000000339","volume":"36","author":"JA Garc\u00eda-Carmona","year":"2021","unstructured":"Garc\u00eda-Carmona JA, Simal-Aguado J, Campos-Navarro MP, Valdivia-Mu\u00f1oz F, Galindo-Tovar A. Evaluation of long-acting injectable antipsychotics with the corresponding oral formulation in a cohort of patients with schizophrenia: a real-world study in Spain. Int Clin Psychopharmacol. 2021;36(1):18\u201324.","journal-title":"Int Clin Psychopharmacol"},{"issue":"5","key":"3329_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.8810","volume":"4","author":"CY Huang","year":"2021","unstructured":"Huang CY, Fang SC, Shao YJ. Comparison of long-acting injectable antipsychotics with oral antipsychotics and suicide and all-cause mortality in patients with newly diagnosed schizophrenia. JAMA Netw Open. 2021;4(5):e218810.","journal-title":"JAMA Netw Open"},{"issue":"11","key":"3329_CR13","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1007\/s12325-018-0786-x","volume":"35","author":"A Shah","year":"2018","unstructured":"Shah A, Xie L, Kariburyo F, Zhang Q, Gore M. Treatment patterns, healthcare resource utilization and costs among schizophrenia patients treated with long-acting injectable versus oral antipsychotics. Adv Ther. 2018;35(11):1994\u20132014.","journal-title":"Adv Ther"},{"issue":"3","key":"3329_CR14","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.clinthera.2021.01.011","volume":"43","author":"M Zhdanava","year":"2021","unstructured":"Zhdanava M, Lin D, Lafeuille MH, et al. Antipsychotic adherence, resource use, and costs before and after the initiation of once-monthly paliperidone palmitate therapy among Medicaid beneficiaries with prior schizophrenia relapse. Clin Ther. 2021;43(3):535\u201348.","journal-title":"Clin Ther"},{"issue":"1","key":"3329_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40801-019-00172-9","volume":"7","author":"C Patel","year":"2020","unstructured":"Patel C, Emond B, Lafeuille MH, et al. Real-world analysis of switching patients with schizophrenia from oral risperidone or oral paliperidone to once-monthly paliperidone palmitate. Drugs Real World Outcomes. 2020;7(1):19\u201329.","journal-title":"Drugs Real World Outcomes"},{"key":"3329_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780195384338.001.0001","volume-title":"Adherence to mental health treatment","author":"PF Buckley","year":"2009","unstructured":"Buckley PF, Foster AE, Patel NC, Wermert A. Adherence to mental health treatment. New York, NY: Oxford University Press; 2009."},{"issue":"suppl 3","key":"3329_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4088\/JCP.15032su1","volume":"77","author":"CU Correll","year":"2016","unstructured":"Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(suppl 3):1\u201324.","journal-title":"J Clin Psychiatry"},{"issue":"13","key":"3329_CR18","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1080\/14656566.2023.2228686","volume":"24","author":"M H\u00f8jlund","year":"2023","unstructured":"H\u00f8jlund M, Correll CU. Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches. Expert Opin Pharmacother. 2023;24(13):1463\u201389.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"3329_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40263-020-00779-5","volume":"35","author":"CU Correll","year":"2021","unstructured":"Correll CU, Kim E, Sliwa JK, et al. Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview. CNS Drugs. 2021;35(1):39\u201359.","journal-title":"CNS Drugs"},{"key":"3329_CR20","unstructured":"Janssen Pharmaceutical Companies. Invega Sustenna; 2021. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/INVEGA+SUSTENNA-pi.pdf. Accessed 1 Oct 2024."},{"key":"3329_CR21","unstructured":"Teva Neuroscience, Inc. Uzedy. Parsippany, NJ; 2024 May. https:\/\/www.uzedy.com\/globalassets\/uzedy\/prescribing-information.pdf. Accessed 1 Oct 2024."},{"issue":"16","key":"3329_CR22","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1016\/j.vaccine.2023.03.018","volume":"41","author":"M Doppen","year":"2023","unstructured":"Doppen M, Kearns C, Weatherall M, et al. When should a longer needle be used for intramuscular injection in obese patients? A combined analysis of New Zealand data. Vaccine. 2023;41(16):2690\u20135.","journal-title":"Vaccine"},{"issue":"5","key":"3329_CR23","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1007\/s12325-023-02455-8","volume":"40","author":"DG Robinson","year":"2023","unstructured":"Robinson DG, Suett M, Wilhelm A, et al. Patient and healthcare professional preferences for characteristics of long-acting injectable antipsychotic agents for the treatment of schizophrenia. Adv Ther. 2023;40(5):2249\u201364.","journal-title":"Adv Ther"},{"issue":"9","key":"3329_CR24","doi-asserted-by":"publisher","first-page":"585","DOI":"10.2165\/11316870-000000000-00000","volume":"48","author":"MN Samtani","year":"2009","unstructured":"Samtani MN, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic. Clin Pharmacokinet. 2009;48(9):585\u2013600.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"3329_CR25","first-page":"829","volume":"25","author":"MN Samtani","year":"2011","unstructured":"Samtani MN, Gopal S, Gassmann-Mayer C, Alphs L, Palumbo JM. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data. CNS Drugs. 2011;25(10):829\u201345.","journal-title":"CNS Drugs"},{"issue":"9","key":"3329_CR26","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/BF03261932","volume":"51","author":"CMT Sherwin","year":"2012","unstructured":"Sherwin CMT, Kiang TKL, Spigarelli MG, Ensom MHH. Fundamentals of population pharmacokinetic modelling: validation methods. Clin Pharmacokinet. 2012;51(9):573\u201390.","journal-title":"Clin Pharmacokinet"},{"key":"3329_CR27","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s40120-025-00723-z","volume":"14","author":"I Perlstein","year":"2025","unstructured":"Perlstein I, Merenlender Wagner A, Elgart A, et al. Population pharmacokinetic modeling of TV-46000, a risperidone long-acting subcutaneous antipsychotic for the treatment of patients with schizophrenia. Neurol Ther. 2025;14:829\u201348.","journal-title":"Neurol Ther"},{"key":"3329_CR28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1471-244X-12-26","volume":"12","author":"D Coppola","year":"2012","unstructured":"Coppola D, Liu Y, Gopal S, et al. A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia. BMC Psychiatry. 2012;12:26.","journal-title":"BMC Psychiatry"},{"issue":"9","key":"3329_CR29","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/psp4.12217","volume":"6","author":"J Korell","year":"2017","unstructured":"Korell J, Green B, Remmerie B, Vermeulen A. Determination of plasma concentration reference ranges for risperidone and paliperidone. CPT Pharmacometrics Syst Pharmacol. 2017;6(9):589\u201395.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"3329_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13089","volume":"72","author":"A Russu","year":"2018","unstructured":"Russu A, Kern Sliwa J, Ravenstijn P, et al. Maintenance dose conversion between oral risperidone and paliperidone palmitate 1\u00a0month: practical guidance based on pharmacokinetic simulations. Int J Clin Pract. 2018;72(6):e13089.","journal-title":"Int J Clin Pract"},{"issue":"12","key":"3329_CR31","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1007\/s00228-024-03763-w","volume":"80","author":"M Chougule","year":"2024","unstructured":"Chougule M, Kollipara S, Mondal S, Ahmed T. A critical review on approaches to generate and validate virtual population for physiologically based pharmacokinetic models: Methodologies, case studies and way forward. Eur J Clin Pharmacol. 2024;80(12):1903\u201322.","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"3329_CR32","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S2215-0366(23)00288-2","volume":"10","author":"JM Kane","year":"2023","unstructured":"Kane JM, Harary E, Eshet R, et al. Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria. Lancet Psychiatry. 2023;10(12):934\u201343.","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"3329_CR33","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/YIC.0b013e32833948fa","volume":"25","author":"S Gopal","year":"2010","unstructured":"Gopal S, Hough DW, Xu H, et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol. 2010;25(5):247\u201356.","journal-title":"Int Clin Psychopharmacol"},{"key":"3329_CR34","unstructured":"Merenlender Wagner A, Perlstein I, Elgart A, et al. Exposure-response analysis to assess the relationships between TV-46000 pharmacokinetic exposure parameters, prevention of impending relapse and adverse events. 34th Annual Psych Congress; San Antonio, Texas. Schizophrenia 2021."},{"issue":"7","key":"3329_CR35","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/cpdd.1078","volume":"11","author":"I Perlstein","year":"2022","unstructured":"Perlstein I, Merenlender Wagner A, Gomeni R, et al. Population pharmacokinetic modeling and simulation of TV-46000: a long-acting injectable formulation of risperidone. Clin Pharmacol Drug Dev. 2022;11(7):865\u201377.","journal-title":"Clin Pharmacol Drug Dev"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03329-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03329-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03329-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T21:02:34Z","timestamp":1762030954000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03329-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3329"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03329-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,8]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by funding from Teva Branded Pharmaceutical Products R&D LLC. Itay Perlstein and Jonathan Meyer have received consultancy fees or honoraria from Teva Branded Pharmaceuticals Products R&D in relation to this study. Vijay Ivaturi is an employee of Pumas-AI Inc., which has received payments from Teva Pharmaceuticals in relation to this study. Ziqi Yue was an employee of Pumas-AI Inc., at the completion of the study and is now affiliated with Beacon Hill Solutions Group LLC. Kelli R. Franzenburg, Mark Suett, Rolf Hansen, Avia Merenlender Wagner, Arti Phatak, and Rajendra Singh are employees and shareholders of Teva Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants. All involved study centers of the original clinical trials received approval by local ethics committees and informed consent was received for all patients. Consent was obtained during the original clinical trials, and no new consent forms were required\/collected for this analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}